Stock ROG ROCHE HOLDING AG
Add to a list

ETFs Roche Holding AG Swiss Exchange

Equities

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange
Other stock markets
 16:30:03 10/04/2026 BST 		5-day change 1st Jan Change
315.60 CHF -0.35% Intraday chart for Roche Holding AG -0.41% -3.84%
04-10 Health Care Down on Retreat from Biotech -- Health Care Roundup DJ
04-10 ROCHE HOLDINGS AG : UBS reiterates its Buy rating ZD

ETFs positioned on Roche Holding AG

Name Varia. Jan 1. Weight AuM
LYXOR DJ SWITZERLAND TITANS 30 (DR) UCITS ETF- CHF ETF Lyxor DJ Switzerland Titans 30 (DR) UCITS ETF- CHF
-.--%9.03% 121 M€
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY ETF Nomura NEXT FUNDS International Equity MSCI-KOKUSAI (Yen-Hedged) ETF - JPY
-1.07%8.46% 26 M€
FIRST TRUST INTERNATIONAL CAPITAL STRENGTH ETF - CAD ETF First Trust International Capital Strength ETF - CAD
+10.52%2.47% 8 M€
DAY HAGAN/NED DAVIS RESEARCH SMART SECTOR INTERNATIONAL ETF - USD ETF Day Hagan/Ned Davis Research Smart Sector International ETF - USD
+4.73%1.77% 32 M€
INDEXIQ FACTORS SUSTAINABLE EUROPE EQUITY UCITS ETF - EUR ETF IndexIQ Factors Sustainable Europe Equity UCITS ETF - EUR
+3.99%1.4% 150 M€
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS - VANGUARD FTSE ALL-WORLD EX-US ETF ETF Vanguard International Equity Index Funds - Vanguard FTSE All-World ex-US ETF
+1.15%0.85% 33,076 M€
HARTFORD MULTIFACTOR DEVELOPED MARKETS (EX-US) ETF - USD ETF Hartford Multifactor Developed Markets (ex-US) ETF - USD
+10.64%0.64% 1,111 M€
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (UNHEDGED) ETF - JPY ETF Nomura NEXT FUNDS International Equity MSCI-KOKUSAI (Unhedged) ETF - JPY
+1.85%0.49% 399 M€
12

Company Profile

Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Sector
Pharmaceuticals
Calendar
04-23 - Earnings release - Q1 2026
More about the company

Income Statement and Estimates

More financial data

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

-
Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

-
Quality

Quality

This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

ESG MSCI

ESG MSCI

The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

AA
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
315.60CHF
Average target price
352.90CHF
Spread / Average Target
+11.82%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ROP Stock
  4. ROG Stock
  5. ETFs Roche Holding AG

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition